Today’s guest on The Long Run podcast is Chris Garabedian. Garabedian is best known for his controversial stint as CEO of Cambridge, Mass.-based Sarepta Therapeutics, the developer of treatments for Duchenne Muscular Dystrophy. Whatever you may think of his tenure there — and the FDA’s decision to approve eteplirsen on a slim reed of clinical trial evidence – there is...Read More
Timmerman Report Gives You Consistent In-Depth Reporting on Biotechnology. Get Your Edge.